The Impel team is attending the American Psychiatric Association 2019 annual meeting in San Francisco, CA and will be presenting data on our first clinical study for our INP105 POD-Olanzapine program. For more information, visit the event page here. ...

SEATTLE, April 30, 2019 — Safety, Tolerability and Comparative Bioavailability Data Support INP104, Impel’s Nasal Drug Candidate for Acute Migraine Results from the Company’s Phase 3 Clinical Program Evaluating INP104 for the Treatment of Acute Migraine Anticipated in Late 2019 Preclinical Data Support Selection of Company’s Novel Formulation of Nasal Levodopa,...

The Impel team will attend the American Academy of Neurology 2019 annual meeting in Philadelphia, PA. Please come visit our booth to learn the latest information about out CNS therapeutics programs. We will also be presenting four posters on our latest research in migraine and Parkinson's. For more information, visit...

Impel's Director of Engineering, Christopher Fuller, will be presenting at the Nasal Drug Delivery Conference in London April 11-12. Presentation: Time: 2pm April 11th Duration: 40 min talkTitle: Developing next generation powder nasal delivery using POD technology Device development effortsFormulation development efforts Unique challenges to powder delivery...

January 2019 - INP104 met the predefined statistical criteria for comparative bioavailability with IV DHE and Migranal. The shorter time to reach Cmax and at 4 times the plasma concentration of DHE in comparison to Migranal combined with a favorable tolerability profile support further investigation of INP104 as an effective,...